TIDMMXCT TIDMTTM
RNS Number : 3036S
MaxCyte, Inc.
08 March 2023
MaxCyte Establishes New Scientific Advisory Board Comprised of
Globally Recognized Experts in Cell Engineering Enabling
Technology
MaxCyte's Scientific Advisory Board will provide guidance to
shape the technical direction of the company's innovation
initiatives focused on the discovery, development and manufacturing
of next-generation, cell-based medicines.
ROCKVILLE, MD, March 8, 2023 - MaxCyte, Inc. , (Nasdaq: MXCT;
LSE: MXCT), a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell-based
therapeutics and to support innovative, cell-based research, today
announced the formation of its new Scientific Advisory Board (SAB)
that will reflect the cutting edge of research in molecular design
and cell engineering, as well as a deep understanding of
translational development, in order to leverage the benefits of
impactful discoveries for therapeutic applications.
"With the formation of our Scientific Advisory Board, we are
expanding the depth and breadth of our leadership team and
scientific expertise with the next generation of leaders in the
field of gene and cell therapy," said Doug Doerfler, President and
CEO of MaxCyte. "These four dynamic scientists are deeply connected
in the scientific community through their work and memberships in
professional societies and will bring the innovation and support
needed to nurture our early-stage projects from beginning to
end."
Each of these individuals has a unique background and brings a
diverse scientific perspective. Supported by deep technical
knowledge, the SAB will help us unlock the power of cells, which
will enhance our R&D activities and portfolio," said Cenk
Sumen, PhD, Chief Scientific Officer of MaxCyte. "With the SAB's
guidance, we aim to provide our clients with innovative cell
engineering applications that accelerate the development of novel
therapies to improve patient outcomes."
Members of the MaxCyte Scientific Advisory Board include:
Oliver Rando, MD, PhD , is a professor in the Biochemistry and
Molecular Biotechnology Department at the University of
Massachusetts Worcester T.H. Chan School of Medicine and principal
investigator within the Rando Lab , which is focused on genomic
approaches to chromatin structure and function, as well as
epigenetic inheritance. He completed his PhD and MD at Stanford
University in Palo Alto, California, working on chromatin
remodeling and T-cell activation in the lab of Jerry Crabtree. Dr.
Rando received a Bachelor of Arts in Biochemistry from Harvard
University in Cambridge, Massachusetts while working on the role of
the proteasome in activation of NF-kB in the lab of Tom
Maniatis.
Marcela Maus, MD, PhD, FABIM , is an associate professor of
medicine at Harvard Medical School and the director of Cellular
Immunotherapy at Massachusetts General Hospital Cancer Center. She
oversees the Maus Lab , which evaluates next-generation,
genetically modified CAR T-cells as immunotherapy in patients with
hematologic malignancies and solid tumors. Dr. Maus holds graduate
degrees (M.D., Ph.D.) from University of Pennsylvania, where she
completed graduate training with Dr. Carl June. Dr. Maus then
trained in internal medicine at University of Pennsylvania and in
hematology and medical oncology at Memorial Sloan Kettering Cancer
Center. She also received a BS in Biology and Literature from
Massachusetts Institute of Technology.
Avery Posey, PhD , is an assistant professor in the Department
of Systems Pharmacology and Translational Therapeutics at the
University of Pennsylvania Perelman School of Medicine. The Posey
Lab focuses on the development of novel targets for CAR-T cell
therapies, strategies to enhance the functional persistence of
CAR-T cells, and the impact of changes in glycosylation on the
tumor immune microenvironment. Dr. Posey holds a PhD in Genetics
from the University of Chicago, and two BS degrees in Biochemistry
and Bioinformatics from the University of Maryland, Baltimore
County (UMBC). He completed his postdoctoral training in the
laboratory of Carl June, where he generated glycosylation-specific
chimeric antigen receptors to precisely target tumor-glycoforms of
MUC1.
Nako Nakatsuka, PhD is a senior scientist/principal investigator
in the Laboratory of Biosensors and Bioelectronics at ETH Zurich in
Switzerland, whose research is focused on harnessing artificial
DNA-based receptors called aptamers for small-molecule biosensing.
Aptamers are integrated into nanoscale biosensors to monitor
neurotransmitters with the goal of unraveling the basic mechanisms
of neurodegenerative diseases. Beyond neuroscience, novel
aptamer-based biosensors are being developed with the vision of
translation for personalized medicine. Dr. Nakatsuka completed her
PhD in Chemistry at the University of California, Los Angeles,
while working in the labs of Anne Andrews and Paul Weiss. Her
thesis exploited aptamers to overcome the conventional bottlenecks
of electronic biosensing of small molecules in complex biological
environments. She also joined the bionanotechnology research lab of
Professor Ipsita Banerjee at Fordham University in New York while
completing her BS degree in Chemistry.
About MaxCyte
MaxCyte is a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell
therapeutics and to support innovative, cell-based research. Over
the past 20 years, we have developed and commercialized our
proprietary Flow Electroporation(R) technology, which facilitates
complex engineering of a wide variety of cells. Our ExPERT(TM)
platform, which is based on our Flow Electroporation technology,
has been designed to support the rapidly expanding cell therapy
market and can be utilized across the continuum of the high-growth
cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx(R),
STx(R) GTx(R) and VLx(TM); a portfolio of proprietary related
processing assemblies or disposables; and software protocols, all
supported by a robust worldwide intellectual property portfolio.
Learn more at maxcyte.com and follow us on Twitter and LinkedIn
.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Seismic Collaborative
Valerie Enes
+1 408-497-8568
valerie@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEANDPESDDEEA
(END) Dow Jones Newswires
March 08, 2023 08:00 ET (13:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024